Verastem Cash on Hand 2011-2023 | VSTM
Verastem cash on hand from 2011 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Verastem Annual Cash on Hand
(Millions of US $) |
| 2022 |
$88 |
| 2021 |
$100 |
| 2020 |
$141 |
| 2019 |
$76 |
| 2018 |
$250 |
| 2017 |
$87 |
| 2016 |
$81 |
| 2015 |
$110 |
| 2014 |
$93 |
| 2013 |
$101 |
| 2012 |
$57 |
| 2011 |
$48 |
| 2010 |
$4 |
Verastem Quarterly Cash on Hand
(Millions of US $) |
| 2023-03-31 |
$111 |
| 2022-12-31 |
$88 |
| 2022-09-30 |
$104 |
| 2022-06-30 |
$94 |
| 2022-03-31 |
$106 |
| 2021-12-31 |
$100 |
| 2021-09-30 |
$103 |
| 2021-06-30 |
$108 |
| 2021-03-31 |
$121 |
| 2020-12-31 |
$141 |
| 2020-09-30 |
$180 |
| 2020-06-30 |
$130 |
| 2020-03-31 |
$135 |
| 2019-12-31 |
$76 |
| 2019-09-30 |
$160 |
| 2019-06-30 |
$187 |
| 2019-03-31 |
$212 |
| 2018-12-31 |
$250 |
| 2018-09-30 |
$146 |
| 2018-06-30 |
$169 |
| 2018-03-31 |
$64 |
| 2017-12-31 |
$87 |
| 2017-09-30 |
$60 |
| 2017-06-30 |
$58 |
| 2017-03-31 |
$73 |
| 2016-12-31 |
$81 |
| 2016-09-30 |
$87 |
| 2016-06-30 |
$93 |
| 2016-03-31 |
$100 |
| 2015-12-31 |
$110 |
| 2015-09-30 |
$120 |
| 2015-06-30 |
$132 |
| 2015-03-31 |
$132 |
| 2014-12-31 |
$93 |
| 2014-09-30 |
$93 |
| 2014-06-30 |
$99 |
| 2014-03-31 |
$106 |
| 2013-12-31 |
$101 |
| 2013-09-30 |
$100 |
| 2013-06-30 |
$57 |
| 2013-03-31 |
$67 |
| 2012-12-31 |
$57 |
| 2012-09-30 |
$47 |
| 2012-06-30 |
$39 |
| 2012-03-31 |
$41 |
| 2011-12-31 |
$48 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
$4 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.203B |
$0.003B |
|
Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
|
